PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH AN ALLOGENEIC B7.1/HLA-A1 TRANSFECTED TUMOR CELL VACCINE (PT 107) IN PATIENTS WITH STAGES IIIB/IV NON-SMALL CELL LUNG CANCER THAT HAVE COMPLETED FIRST LINE CHEMOTHERAPY

PIQUE THERAPEUTICS INC0 sites100 target enrollmentTBD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Health Condition 1: null- Advanced non-small cell lung cancer (Stages IIIB/IV) who have failed first line of chemotherapy
Sponsor: PIQUE THERAPEUTICS INC
Enrollment: 100
Status: Active, not recruiting
Last Updated: 4 years ago

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Sponsor

•1\. Patients with documented stage IIIB or IV advanced or metastatic NSCLC who have completed 4\-6 cycles of platinum based chemotherapy, with or without radiation, and have either stable disease or have experienced disease progression (additional prior adjuvant chemotherapy is permitted).
•2\. ECOG performance status 0\-2\.
•3\. Presence of at least one measurable lesion according to RECIST criteria.
•4\. Renal Requirements: The calculated creatinine clearance must be at least 50 ml/min.
•5\. Pulmonary Function Requirements
•All patients will undergo evaluation of pulmonary function prior to enrollment. Patients should have a FeV1 more than 30% of the predicted value and/or DLCO more than 30% of the predicted value with a PCO2 \< 45mm. Any patient enrolled in the protocol whose respiratory symptoms have experienced marked deterioration not related to a known cause (e.g. pneumonia, CHF or PE) will have request PFT evaluation and if the above parameters are not fulfilled will be excluded from the protocol.
•6\. Age \> or \= 18 years.
•7\. Signed informed consent.
•8\. ANC \> or \=1000/mm3; PLT\> or \= 80,000/mm3\.
•9\. Hemoglobin \> or \= 10 g/dL.

•1\. Small cell carcinoma of the lung.
•2\. Existing autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease etc; colitis, inflammatory bowel disease or pancreatitis within 10 years of study.
•3\. Other active malignancies present within the past three years, except for basal and / or squamous cell carcinoma(s) or in situ cervical cancer.
•4\. Concomitant steroid or other immunosuppressive therapy.
•5\. Active infection, or less than 7 days since therapy for acute infections.
•6\. Pericardial effusion.
•7\. Currently receiving chemotherapy for another condition (such as arthritis).
•8\. Active or symptomatic cardiac disease such as congestive heart failure, angina pectoris or recent myocardial infarction.
•9\. Pregnant or lactating women (negative test for pregnancy required of women of child bearing potential).
•10\. Refusal in fertile men or women to use effective birth control measures during and for six months after the completion of treatment on study.